TY - JOUR
T1 - Antibody-based formats to target glioblastoma
T2 - overcoming barriers to protein drug delivery
AU - Ghosh, Saikat
AU - Huda, Pie
AU - Fletcher, Nicholas L.
AU - Howard, Christopher B.
AU - Walsh, Brad
AU - Campbell, Douglas
AU - Pinkham, Mark B.
AU - Thurecht, Kristofer J.
PY - 2022/5/2
Y1 - 2022/5/2
N2 - Glioblastoma (GB) is recognized as the most aggressive form of primary brain cancer. Despite advances in treatment strategies that include surgery, radiation, and chemotherapy, the median survival time (∼15 months) of patients with GB has not significantly improved. The poor prognosis of GB is also associated with a very high chance of tumor recurrence (∼90%), and current treatment measures have failed to address the complications associated with this disease. However, targeted therapies enabled through antibody engineering have shown promise in countering GB when used in combination with conventional approaches. Here, we discuss the challenges in conventional as well as future GB therapeutics and highlight some of the known advantages of using targeted biologics to overcome these impediments. We also review a broad range of potential alternative routes that could be used clinically to administer anti-GB biologics to the brain through evasion of its natural barriers.
AB - Glioblastoma (GB) is recognized as the most aggressive form of primary brain cancer. Despite advances in treatment strategies that include surgery, radiation, and chemotherapy, the median survival time (∼15 months) of patients with GB has not significantly improved. The poor prognosis of GB is also associated with a very high chance of tumor recurrence (∼90%), and current treatment measures have failed to address the complications associated with this disease. However, targeted therapies enabled through antibody engineering have shown promise in countering GB when used in combination with conventional approaches. Here, we discuss the challenges in conventional as well as future GB therapeutics and highlight some of the known advantages of using targeted biologics to overcome these impediments. We also review a broad range of potential alternative routes that could be used clinically to administer anti-GB biologics to the brain through evasion of its natural barriers.
KW - antibody
KW - antibody fragments
KW - blood-brain barrier
KW - glioblastoma
KW - molecular imaging
KW - nuclear medicine
UR - http://www.scopus.com/inward/record.url?scp=85128693618&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.1c00996
DO - 10.1021/acs.molpharmaceut.1c00996
M3 - Article
C2 - 35438509
AN - SCOPUS:85128693618
SN - 1543-8384
VL - 19
SP - 1233
EP - 1247
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 5
ER -